Novel anti-HIV agents are still needed to overcome resistance issues, in particular inhibitors acting against novel viral targets. The ribonuclease H (RNase H) function of the reverse transcriptase (RT) represents a validated and promising target, and no inhibitor has reached the clinical pipeline yet. Here, we present rationally designed non-diketo acid selective RNase H inhibitors (RHIs) based on the quinolinone scaffold starting from former dual integrase (IN)/RNase H quinolinonyl diketo acids. Several derivatives were synthesized and tested against RNase H and viral replication and found active at micromolar concentrations. Docking studies within the RNase H catalytic site, coupled with site-directed mutagenesis, and Mg titration experiments demonstrated that our compounds coordinate the Mg cofactor and interact with amino acids of the RNase H domain that are highly conserved among naïve and treatment-experienced patients. In general, the new inhibitors influenced also the polymerase activity of RT but were selective against RNase H vs the IN enzyme.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8279492PMC
http://dx.doi.org/10.1021/acs.jmedchem.1c00535DOI Listing

Publication Analysis

Top Keywords

non-diketo acid
8
reverse transcriptase
8
selective rnase
8
rnase
6
quinolinonyl non-diketo
4
acid derivatives
4
inhibitors
4
derivatives inhibitors
4
inhibitors hiv-1
4
hiv-1 ribonuclease
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!